Go online to PeerView.com/HBK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia, as well as offers practical insight on how clinical pharmacists may take an active role in improving clinical outcomes in patients with CKD. Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD, Recognize the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia associated with CKD in both nondialysis- and dialysis-dependent patients, Apply evidence-based strategies to effectively coordinate with the healthcare team to identify patients with anemia-associated CKD who would likely derive benefit from treatment with a HIF-PH inhibitor.
View all episodes
